Vilaseca, VG, Perez, ES, Fabrego, IE, Peral, IL, Prat, AM. Wolf's isotopic phenomenon in a patient with T-cell lymphoblastic lymphoma. MEDICINA CLINICA. 2025; 165(5)DOI:10.1016/j.medcli.2025.107073. PMID:40543401. IF:2.100(Q2/3D).

Fasanella, MG, Mozos, A, Briones, J, Nomdedeu, JF, Novelli, S. Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single-Center Retrospective Analysis. Cancer Reports. 2025; 8(10)DOI:10.1002/cnr2.70356. PMID:41031578. IF:(Q/D).

Tolosa-Ridao, C, González, MB, Gómez, MA, Fox, L, Artigas, MDP, Santamaria, A, González, MDQ, Salinas, AS, Camacho, JMS, Alvaro, VI, Abdallahi-Lefdil, Z, Navascues, JC, Pardo, L, Fernández-Luis, S, Suárez, LPV, Villar, S, Beorlegui-Murillo, P, Esquirol, A, García, II, Ribes-Amorós, J, Lavilla, E, Lopez-Marín, J, Basalobre, P, Filaferro, S, Cedillo, A, Bento, L, Sureda, A, Salas, MQ. Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study. BRITISH JOURNAL OF HAEMATOLOGY. 2025; 207(4)DOI:10.1111/bjh.70068. PMID:40796522. IF:3.800(Q1/3D).

Osuna-Gómez, R, López-Pardo, J, Mulet, M, Nomdedéu, J, Cantó, E, Ortin, R, Cayuela, AS, Ortiz, MA, Guinart-Cuadra, A, Vidal, S. Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma. Pharmaceutics. 2025; 17(10)DOI:10.3390/pharmaceutics17101278. PMID:41155915. IF:5.500(Q1/1D).